393 related articles for article (PubMed ID: 8353865)
1. Comparative mechanisms of antiarrhythmic drug action in experimental atrial fibrillation. Importance of use-dependent effects on refractoriness.
Wang J; Bourne GW; Wang Z; Villemaire C; Talajic M; Nattel S
Circulation; 1993 Sep; 88(3):1030-44. PubMed ID: 8353865
[TBL] [Abstract][Full Text] [Related]
2. Class III antiarrhythmic drug action in experimental atrial fibrillation. Differences in reverse use dependence and effectiveness between d-sotalol and the new antiarrhythmic drug ambasilide.
Wang J; Feng J; Nattel S
Circulation; 1994 Oct; 90(4):2032-40. PubMed ID: 7923691
[TBL] [Abstract][Full Text] [Related]
3. The class III antiarrhythmic drugs dofetilide and sotalol prevent AF induction by atrial premature complexes at doses that fail to terminate AF.
Derakhchan K; Villemaire C; Talajic M; Nattel S
Cardiovasc Res; 2001 Apr; 50(1):75-84. PubMed ID: 11282080
[TBL] [Abstract][Full Text] [Related]
4. Effects of procainamide and dl-sotalol on the changes of atrial electrophysiology induced by high current stimulation.
Yu WC; Chen SA; Tai CT; Wen ZC; Feng AN; Ding YA; Chang MS
Pacing Clin Electrophysiol; 1998 Nov; 21(11 Pt 1):2064-9. PubMed ID: 9826857
[TBL] [Abstract][Full Text] [Related]
5. Mechanism of flecainide's antiarrhythmic action in experimental atrial fibrillation.
Wang Z; Pagé P; Nattel S
Circ Res; 1992 Aug; 71(2):271-87. PubMed ID: 1628386
[TBL] [Abstract][Full Text] [Related]
6. Old and new antiarrhythmic drugs for converting and maintaining sinus rhythm in atrial fibrillation: comparative efficacy and results of trials.
Naccarelli GV; Wolbrette DL; Khan M; Bhatta L; Hynes J; Samii S; Luck J
Am J Cardiol; 2003 Mar; 91(6A):15D-26D. PubMed ID: 12670638
[TBL] [Abstract][Full Text] [Related]
7. Effects of pilsicainide and propafenone on vagally induced atrial fibrillation: role of suppressant effect in conductivity.
Iwasa A; Okumura K; Tabuchi T; Tsuchiya T; Tsunoda R; Matsunaga T; Tayama S; Yasue H
Eur J Pharmacol; 1998 Aug; 356(1):31-40. PubMed ID: 9761421
[TBL] [Abstract][Full Text] [Related]
8. Insights into mechanisms of antiarrhythmic drug action from experimental models of atrial fibrillation.
Nattel S; Bourne G; Talajic M
J Cardiovasc Electrophysiol; 1997 Apr; 8(4):469-80. PubMed ID: 9106433
[TBL] [Abstract][Full Text] [Related]
9. Transitions among atrial fibrillation, atrial flutter, and sinus rhythm during procainamide infusion and vagal stimulation in dogs with sterile pericarditis.
Pagé PL; Hassanalizadeh H; Cardinal R
Can J Physiol Pharmacol; 1991 Jan; 69(1):15-24. PubMed ID: 2036596
[TBL] [Abstract][Full Text] [Related]
10. Postrepolarization refractoriness versus conduction slowing caused by class I antiarrhythmic drugs: antiarrhythmic and proarrhythmic effects.
Kirchhof PF; Fabritz CL; Franz MR
Circulation; 1998 Jun; 97(25):2567-74. PubMed ID: 9657478
[TBL] [Abstract][Full Text] [Related]
11. Effects of procainamide and propafenone on the composition of the excitable gap in canine atrial reentry tachycardia.
Derakhchan K; Pagé P; Lambert C; Kus T
J Pharmacol Exp Ther; 1994 Jul; 270(1):47-54. PubMed ID: 8035342
[TBL] [Abstract][Full Text] [Related]
12. Therapy of refractory symptomatic atrial fibrillation and atrial flutter: a staged care approach with new antiarrhythmic drugs.
Antman EM; Beamer AD; Cantillon C; McGowan N; Friedman PL
J Am Coll Cardiol; 1990 Mar; 15(3):698-707. PubMed ID: 2303641
[TBL] [Abstract][Full Text] [Related]
13. Effects of procainamide and sotalol on restitution properties, dispersion of refractoriness, and ventricular fibrillation activation patterns in pigs.
Jin Q; Chen X; Smith WM; Ideker RE; Huang J
J Cardiovasc Electrophysiol; 2008 Oct; 19(10):1090-7. PubMed ID: 18479337
[TBL] [Abstract][Full Text] [Related]
14. Electrophysiologic Effects of the New Class III Antiarrhythmic Drug Dofetilide in an Experimental Canine Model of Pacing-induced Atrial Fibrillation.
Feld GK; Cha Y
J Cardiovasc Pharmacol Ther; 1997 Jul; 2(3):195-203. PubMed ID: 10684458
[TBL] [Abstract][Full Text] [Related]
15. Mechanisms of termination of reentrant atrial arrhythmias by class I and class III antiarrhythmic agents.
Spinelli W; Hoffman BF
Circ Res; 1989 Dec; 65(6):1565-79. PubMed ID: 2510953
[TBL] [Abstract][Full Text] [Related]
16. Effects of a new class III antiarrhythmic drug nibentan in a canine model of vagally mediated atrial fibrillation.
Fedorov VV; Sharifov OF; Beloshapko GG; Yushmanova AV; Rosenshtraukh LV
J Cardiovasc Pharmacol; 2000 Jul; 36(1):77-89. PubMed ID: 10892664
[TBL] [Abstract][Full Text] [Related]
17. Sotalol and type IA drugs in combination prevent recurrence of sustained ventricular tachycardia.
Dorian P; Newman D; Berman N; Hardy J; Mitchell J
J Am Coll Cardiol; 1993 Jul; 22(1):106-13. PubMed ID: 8509529
[TBL] [Abstract][Full Text] [Related]
18. Pharmacologic conversion and suppression of experimental canine atrial flutter: differing effects of d-sotalol, quinidine, and lidocaine and significance of changes in refractoriness and conduction.
Feld GK; Venkatesh N; Singh BN
Circulation; 1986 Jul; 74(1):197-204. PubMed ID: 3708774
[TBL] [Abstract][Full Text] [Related]
19. Effects of antiarrhythmic drugs on canine atrial flutter due to reentry: role of prolongation of refractory period and depression of conduction to excitable gap.
Inoue H; Yamashita T; Nozaki A; Sugimoto T
J Am Coll Cardiol; 1991 Oct; 18(4):1098-104. PubMed ID: 1910060
[TBL] [Abstract][Full Text] [Related]
20. Propafenone versus sotalol for suppression of recurrent symptomatic atrial fibrillation.
Reimold SC; Cantillon CO; Friedman PL; Antman EM
Am J Cardiol; 1993 Mar; 71(7):558-63. PubMed ID: 8438741
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
